Search Results

You are looking at 1 - 10 of 672 items for :

  • "colorectal cancer" x
  • Refine by Access: All x
Clear All
Full access

Colorectal Cancer Screening

Randall W. Burt, Jamie A. Cannon, Donald S. David, Dayna S. Early, James M. Ford, Francis M. Giardiello, Amy L. Halverson, Stanley R. Hamilton, Heather Hampel, Mohammad K. Ismail, Kory Jasperson, Jason B. Klapman, Audrey J. Lazenby, Patrick M. Lynch, Robert J. Mayer, Reid M. Ness, Dawn Provenzale, M. Sambasiva Rao, Moshe Shike, Gideon Steinbach, Jonathan P. Terdiman, David Weinberg, Mary Dwyer, and Deborah Freedman-Cass

Colorectal cancer (CRC) is the fourth most frequently diagnosed cancer in the United States. In 2012, an estimated 102,480 new cases of colon cancer and 40,340 new cases of rectal cancer will occur in the United States. During the same year, an estimated 50

Full access

Adolescent and Young Adult Colorectal Cancer

Joleen M. Hubbard and Axel Grothey

Incidence of Colorectal Cancer in Adolescents and Young Adults The incidence of colorectal cancer (CRC) in young adults is relatively low. CRC is typically a disease of older adults, with the average age of colon cancer diagnosis approaching

Full access

Biomarker Use in Colorectal Cancer Therapy

Robin K. Kelley, Grace Wang, and Alan P. Venook

(MSI) testing in management of patients with stage II colon cancer Describe the role of KRAS mutational analysis in management of patients with metastatic colorectal cancers Describe the role of BRAF mutational analysis in management of patients with

Full access

Sessile Serrated Polyps: An Important Route to Colorectal Cancer

Matthew F. Kalady

cytoplasm. 2 Expert opinion suggests that SSA/Ps with cytologic dysplasia be considered to have at least the same colorectal cancer (CRC) risk as adenomas with high-grade dysplasia. 2 Another form of dysplasia can be seen in SSA/Ps, termed serrated

Full access

A Real-World Comparison of Regorafenib and Trifluridine/Tipiracil in Refractory Metastatic Colorectal Cancer in the United States

Christopher Nevala-Plagemann, Shashank Sama, Jian Ying, Jincheng Shen, Benjamin Haaland, Vaia Florou, and Ignacio Garrido-Laguna

Background Colorectal cancer (CRC) remains among the largest contributors of cancer mortality, with >50,000 projected deaths in 2022, making it the second leading cause of cancer death in the United States. 1 For patients with advanced or

Full access

Modification and Implementation of NCCN Guidelines™ on Colon Cancer in the Middle East and North Africa Region

Fikri İçli, Hakan Akbulut, Shouki Bazarbashi, Mehmet Ayhan Kuzu, Mohandas K. Mallath, Kakil Ibrahim Rasul, Scott Strong, Aamir Ali Syed, Faruk Zorlu, and Paul F. Engstrom

colorectal cancer should ideally be based on evidence-based medicine, standardized practices do not exist in other parts of the world. The social, cultural, and economic differences among the countries may be responsible for this lack of standard management

Full access

Incident Cardiovascular Diseases Among Survivors of High-Risk Stage II–III Colorectal Cancer: A Cluster-Wide Cohort Study

Shing Fung Lee, Pui Lam Yip, Balamurugan A. Vellayappan, Cheng Ean Chee, Lea Choung Wong, Eric Yuk-Fai Wan, Esther Wai-Yin Chan, Chak-Fei Lee, Francis Ann-Shing Lee, and Miguel Angel Luque-Fernandez

Background A general decline in mortality in colorectal cancer (CRC) in recent decades is attributed to improvements in treatment, changing patterns in CRC risk factors, and screening. 1 , 2 CRC is the one of the most common cancers among

Full access

Emerging Treatments in Recurrent and Metastatic Colorectal Cancer

Kristen Keon Ciombor and Tanios Bekaii-Saab

personalized therapy for patients with mCRC Colorectal cancer (CRC) is both the third most prevalent and third most fatal tumor type in the United States, with an estimated 143,460 new cases and 51,690 deaths in 2012 alone. 1 Although surgical resection

Full access

Metastatic Colorectal Cancer: Lessons Learned, Future Possibilities

Alan P. Venook

At the NCCN 21st Annual Conference, Alan P. Venook, MD, from UCSF Helen Diller Family Comprehensive Cancer Center, looked back for “lessons learned” in the treatment of metastatic colorectal cancer (mCRC) and peered into the future to gauge how

Full access

Colorectal Cancer Screening

Randall W. Burt, James S. Barthel, Kelli Bullard Dunn, Donald S. David, Ernesto Drelichman, James M. Ford, Francis M. Giardiello, Stephen B. Gruber, Amy L. Halverson, Stanley R. Hamilton, Mohammad K. Ismail, Kory Jasperson, Audrey J. Lazenby, Patrick M. Lynch, Edward W. Martin Jr., Robert J. Mayer, Reid M. Ness, Dawn Provenzale, M. Sambasiva Rao, Moshe Shike, Gideon Steinbach, Jonathan P. Terdiman, and David Weinberg

Colorectal Cancer Screening Clinical Practice Guidelines in Oncology NCCN Categories of Evidence and Consensus Category 1: The recommendation is based on high-level evidence (e.g., randomized controlled trials) and there is uniform NCCN